INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023
Safety and Immunological data from both cohorts of the recently completed Phase 1/2 trial will be presented on
"We are pleased that lead investigator Dr.
Details of the ABEA at COSM presentation are as follows:
Title: Phase 1/2 Open-label, Multicenter Trial Of INO-3107 With Electroporation In Adult Patients With HPV-6 And/or HPV-11-associated Recurrent Respiratory Papillomatosis: Interim Analysis
Session: ABEA Scientific Session III: Voice
Session Date and Time: Friday, May 5, 2023,
Location: 304/306 (Hynes)
The presentation will include new safety, immunological, and demographic data from both cohorts of a Phase 1/2 trial evaluating the safety, tolerability, immunogenicity, and efficacy of INO-3107 in 32 patients with HPV-6 and/or HPV-11-associated RRP.
About RRP
RRP is a debilitating and rare disease caused primarily by HPV-6 and/or HPV-11. RRP is characterized by the development of small, wart-like growths, or papillomas, in the respiratory tract. While papillomas are generally benign, they can cause severe, life-threatening airway obstruction and respiratory complications. RRP can also significantly affect quality of life for patients by affecting the voice box, limiting the ability to speak effectively. Surgery to remove papillomas is the standard of care for RRP; however, the papillomas often grow back because the underlying HPV infection has not been eradicated.
The most widely cited
About INO-3107
INO-3107 is INOVIO's clinical-stage DNA medicine product candidate being developed as a potential treatment for RRP. INO-3107 is designed to elicit a targeted T cell response against HPV-6 and HPV-11, the HPV types responsible for causing RRP among other HPV-related diseases. These targeted T cells are designed to seek out and kill infected cells, with the aim of potentially preventing or slowing the growth of new papillomas. INO-3107 received Orphan Drug Designation from the
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases. INOVIO's DNA medicines in development are delivered using its investigational proprietary smart device, CELLECTRA®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.
Contacts
Media:
Investors:
SOURCE